VACCITECH PLC (VACC) Fundamental Analysis & Valuation
NASDAQ:VACC • US91864C1071
Current stock price
5 USD
+0.51 (+11.36%)
At close:
4.9 USD
-0.1 (-2%)
After Hours:
This VACC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. VACC Profitability Analysis
1.1 Basic Checks
- In the past year VACC has reported negative net income.
- In the past year VACC has reported a negative cash flow from operations.
1.2 Ratios
- Looking at the Return On Assets, with a value of -22.32%, VACC belongs to the top of the industry, outperforming 80.10% of the companies in the same industry.
- Looking at the Return On Equity, with a value of -25.29%, VACC belongs to the top of the industry, outperforming 83.25% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -22.32% | ||
| ROE | -25.29% | ||
| ROIC | N/A |
ROA(3y)-17.03%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for VACC so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. VACC Health Analysis
2.1 Basic Checks
- VACC does not have a ROIC to compare to the WACC, probably because it is not profitable.
- VACC has more shares outstanding than it did 1 year ago.
- There is no outstanding debt for VACC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- An Altman-Z score of 3.18 indicates that VACC is not in any danger for bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 3.18, VACC is in the better half of the industry, outperforming 76.29% of the companies in the same industry.
- VACC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.18 |
ROIC/WACCN/A
WACC9.06%
2.3 Liquidity
- VACC has a Current Ratio of 15.26. This indicates that VACC is financially healthy and has no problem in meeting its short term obligations.
- The Current ratio of VACC (15.26) is better than 88.06% of its industry peers.
- A Quick Ratio of 15.26 indicates that VACC has no problem at all paying its short term obligations.
- VACC has a better Quick ratio (15.26) than 88.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 15.26 | ||
| Quick Ratio | 15.26 |
3. VACC Growth Analysis
3.1 Past
- VACC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -4723.33%.
- The Revenue for VACC has decreased by -58.53% in the past year. This is quite bad
- Measured over the past years, VACC shows a very strong growth in Revenue. The Revenue has been growing by 86.87% on average per year.
EPS 1Y (TTM)-4723.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-251.22%
Revenue 1Y (TTM)-58.53%
Revenue growth 3Y86.87%
Revenue growth 5YN/A
Sales Q2Q%-98.04%
3.2 Future
- The Earnings Per Share is expected to decrease by -98.17% on average over the next years. This is quite bad
- Based on estimates for the next years, VACC will show a very negative growth in Revenue. The Revenue will decrease by -60.57% on average per year.
EPS Next Y-1733.53%
EPS Next 2Y-304.24%
EPS Next 3Y-153.1%
EPS Next 5Y-98.17%
Revenue Next Year-95.74%
Revenue Next 2Y-84.84%
Revenue Next 3Y-75.62%
Revenue Next 5Y-60.57%
3.3 Evolution
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. VACC Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for VACC. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VACC. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- VACC's earnings are expected to decrease with -153.10% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-304.24%
EPS Next 3Y-153.1%
5. VACC Dividend Analysis
5.1 Amount
- VACC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
VACC Fundamentals: All Metrics, Ratios and Statistics
5
+0.51 (+11.36%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-09 2023-11-09/amc
Earnings (Next)N/A N/A
Inst Owners38.61%
Inst Owner Change-13.85%
Ins Owners26.92%
Ins Owner Change0%
Market Cap192.73M
Revenue(TTM)13.42M
Net Income(TTM)-54.93M
Analysts81.82
Price Target9.5 (90%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.31%
Min EPS beat(2)-11.12%
Max EPS beat(2)6.51%
EPS beat(4)2
Avg EPS beat(4)32.49%
Min EPS beat(4)-30.8%
Max EPS beat(4)165.36%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-57.42%
Min Revenue beat(2)-69.41%
Max Revenue beat(2)-45.42%
Revenue beat(4)1
Avg Revenue beat(4)-11.6%
Min Revenue beat(4)-69.41%
Max Revenue beat(4)91.15%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-24.49%
EPS NQ rev (1m)0%
EPS NQ rev (3m)7.13%
EPS NY rev (1m)0%
EPS NY rev (3m)2.7%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)400%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.22%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 14.36 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.89 | ||
| P/tB | 1.08 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.45
EYN/A
EPS(NY)-1.91
Fwd EYN/A
FCF(TTM)-0.73
FCFYN/A
OCF(TTM)-0.51
OCFYN/A
SpS0.35
BVpS5.63
TBVpS4.63
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -22.32% | ||
| ROE | -25.29% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-17.03%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.05
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 174.45% | ||
| Cap/Sales | 63.48% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 15.26 | ||
| Quick Ratio | 15.26 | ||
| Altman-Z | 3.18 |
F-Score2
WACC9.06%
ROIC/WACCN/A
Cap/Depr(3y)156.82%
Cap/Depr(5y)N/A
Cap/Sales(3y)149.12%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4723.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-251.22%
EPS Next Y-1733.53%
EPS Next 2Y-304.24%
EPS Next 3Y-153.1%
EPS Next 5Y-98.17%
Revenue 1Y (TTM)-58.53%
Revenue growth 3Y86.87%
Revenue growth 5YN/A
Sales Q2Q%-98.04%
Revenue Next Year-95.74%
Revenue Next 2Y-84.84%
Revenue Next 3Y-75.62%
Revenue Next 5Y-60.57%
EBIT growth 1Y-82.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-1689.94%
EBIT Next 3Y-191.11%
EBIT Next 5YN/A
FCF growth 1Y39.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y55.71%
OCF growth 3YN/A
OCF growth 5YN/A
VACCITECH PLC / VACC Fundamental Analysis FAQ
What is the fundamental rating for VACC stock?
ChartMill assigns a fundamental rating of 3 / 10 to VACC.
What is the valuation status for VACC stock?
ChartMill assigns a valuation rating of 0 / 10 to VACCITECH PLC (VACC). This can be considered as Overvalued.
What is the profitability of VACC stock?
VACCITECH PLC (VACC) has a profitability rating of 1 / 10.